Published in Women's Health Weekly, October 25th, 1999
Vertebral fractures in particular are a common consequence of osteoporosis and are considered a hallmark of osteoporosis in postmenopausal women, since the condition is hard to detect until there is a fracture.
An important goal of research into osteoporosis treatments, therefore, has been preventing fractures.
In a new study, postmenopausal women with osteoporosis who took daily doses of the investigational drug risedronate reduced their risk of new bone fractures, according to an article in the October 13,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.